(Updated - May 26, 2026 4:26 PM EDT)
Kardigan, Inc on Tuesday filed registration documents for a proposed initial public offering on the Nasdaq exchange, indicating it would trade under the ticker "KARD." The filing identifies the company as a clinical-stage developer focused on precision therapeutics for cardiovascular conditions that lack approved therapies.
In its statement of purpose, the company says it seeks to develop multiple targeted cardiovascular treatments concurrently and emphasizes an approach that addresses the underlying causes of specific diseases rather than broader, downstream symptoms. Kardigan described its mission as bringing patients closer to cures by leveraging expertise in cardiovascular biology, patient data, and advanced analytics to accelerate the discovery and development of therapies.
"Kardigan is a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. Our mission is to develop multiple targeted cardiovascular treatments in parallel that bring people with cardiovascular diseases closer to the cures they deserve. We leverage deep domain expertise in cardiovascular biology, patient data, and advanced analytics to accelerate drug discovery and development, aiming to deliver impactful therapies efficiently and at scale.
Our management team includes leaders from MyoKardia, Inc. ("MyoKardia") with a proven track record in cardiovascular drug development, including the successful development and approval of mavacamten for hypertrophic cardiomyopathy.
Cardiovascular disease is the leading cause of death worldwide, yet innovation has lagged due to drug development focused on broad, downstream, symptom-focused approaches despite disease heterogeneity and genetic variability, resulting in incremental advances and lengthy clinical trials. Kardigan is committed to overcoming these challenges by advancing precision medicines that target the fundamental drivers of cardiovascular conditions, aiming to deliver meaningful improvements in patient outcomes."
The filing also lists J.P. Morgan, Jefferies, Leerink Partners and TD Cowen as underwriters for the proposed offering.
Context and implications
The company's filing signals intentions to access public capital markets to support development of its pipeline of precision cardiovascular treatments. Kardigan highlights management experience drawn from MyoKardia, noting leadership that participated in the development and approval of mavacamten for hypertrophic cardiomyopathy. The firm frames its strategy around targeting disease drivers and applying advanced analytics to accelerate R&D timelines.
What is not provided in the filing - The registration documents included in the filing note the company's strategic priorities and planned use of technology and expertise, but the filing does not detail offering size, proposed share price, expected proceeds, or specific clinical timelines for individual programs.
The company and its chosen underwriters will proceed through the standard regulatory and market steps for an IPO as data room disclosures, regulatory review, and marketing to investors continue prior to any final offering.